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Background/Rationale: Patients are admitted to Intensive care units (ICUs) either
because they need close monitoring despite a low risk of hospital mortality (LRM
group) or to receive ICU specific active treatments (AT group). The characteristics and
differential outcomes of LRM patients vs. AT patients in Neurocritical Care Units are poorly
understood.
Methods: We classified 1,702 patients admitted to our tertiary and quaternary
care center Neuroscience-ICU in 2016 and 2017 into LRM vs. AT groups. We
compared demographics, admission diagnosis, goal of care status, readmission rates
and managing attending specialty extracted from the medical record between groups.
Acute Physiology, Age and Chronic Health Evaluation (APACHE) IVa risk predictive
modeling was used to assess comparative risks for ICU and hospital mortality and length
of stay between groups.
Results: 56.9% of patients admitted to our Neuroscience-ICU in 2016 and
2017 were classified as LRM, whereas 43.1% of patients were classified as AT.
While demographically similar, the groups differed significantly in all risk predictive
outcome measures [APACHE IVa scores, actual and predicted ICU and hospital
mortality (p < 0.0001 for all metrics)]. The most common admitting diagnosis overall,
cerebrovascular accident/stroke, was represented in the LRM and AT groups with
similar frequency [24.3 vs. 21.3%, respectively (p = 0.15)], illustrating that further
differentiating factors like symptom duration, neurologic status and its dynamic changes
and neuro-imaging characteristics determine the indication for active treatment vs.
observation. Patients with intracranial hemorrhage/hematoma were significantly more
likely to receive active treatments as opposed to having a primary focus on monitoring
[13.6 vs. 9.8%, respectively (p = 0.017)].
Conclusion: The majority of patients admitted to our Neuroscience ICU (56.9%) had
<10% hospital mortality risk and a focus on monitoring, whereas the remaining 43.1%
of patients received active treatments in their first ICU day. LRM Patients exhibited
significantly lower APACHE IVa scores, ICU and hospital mortality rates compared to
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AT patients. Observed-over-expected ICU and hospital mortality ratios were better than
predicted by APACHE IVa for low risk monitored patients and close to prediction for
actively treated patients, suggesting that at least a subset of LRM patients may safely
and more cost effectively be cared for in intermediate level care settings.
Keywords: low risk monitor, telemedicine, tele-ICU, electronic ICU, neuroscience ICU, neuro-ICU
INTRODUCTION
General guidelines for intensive care unit (ICU) admission,
discharge and triage have been developed by the Society of
Critical Care Medicine in 1999 and updated in 2016 (1). They
provide an important framework to guide triage and ICU bed
utilization, but inevitably represent only general guidelines.
Conceptually, all ICU bed utilization approaches attempt to
factor in acuity of the patient’s illness at presentation as well
as changes of acuity over time combined with complexity of
management. ICU patient populations can also dichotomously
be divided into those who receive active ICU treatments for
impaired organ functions and those who are not, but are being
monitored because they are at high risk of impaired or worsening
organ function despite an overall low hospital mortality risk.
Given that ICU beds are a precious resource in hospitals and
societal forces will place pressures on health care spending,
understanding optimal ICU utilization will be paramount in the
next two decades (2).
APACHE
A multitude of tools have been developed for ICU performance
assessments (3) and comprehensive systematic performance
measurements (4). Acute Physiology, Age and Chronic Health
Evaluation (APACHE) scoring was developed in the late 1970s
as a tool to describe groups of patients based on severity
of illness and enable risk prediction modeling for ICU and
hospital mortality and length of stay (5). Over four consecutive
iterations APACHE [APACHE in 1981 (5), APACHE II in
1985 (6), APACHE III in 1991 (7) and APACHE IV in 2006
(8)] has evolved into and emerged as the gold standard risk
prediction tool for critically ill patients. There are a variety of
well-validated disease or condition specific risk prediction tools
in Neurocritical Care, among them the Hunt&Hess (HH) and
World Federation of Neurological Surgeons (WFNS) grading
systems for Subarachnoid Hemorrhage (SAH), the intracerebral
hemorrhage (ICH) score or the ischemic Stroke Prediction Risk
Score (iScore). These risk prediction tools were developed and
validated to guide clinical care and generate comparative risk
predictions for patients with specific diagnoses. In other words,
they generate comparative risk predictions within diagnostic
categories but fall short when it comes to generating comparative
predictions across the spectrum of critical illness with a unifying
validated methodology.
Abbreviations: ICU, intensive care unit; LRM, low risk monitor; AT, active
treatment; APACHE, Acute Physiology, Age and Chronic Health Evaluation; SAH,
subarachnoid hemorrhage; ICH, intracerebral hemorrhage; TISS, therapeutic
intervention scoring system; LOS, length of stay; US, United States.
Active Treatment vs. Monitoring
In parallel to capturing the acuity of ICU patients, the
Therapeutic Intervention Scoring System (TISS) was developed
in 1974 (9) and updated in 1983 (10) to classify critically ill
patients by therapeutic interventions. The TISS nomenclature
categorizes patients receiving one or more of 35 active ICU
treatments (AT) as specified by the TISS during their first
24 h in the ICU are “actively treated,” whereas those who do
not receive any active treatments in their first ICU day are
categorized as “monitored.” The same group that developed
APACHE published on further predictive multivariate equations
in 1995 that aim to estimate the probability of need of life-
supporting treatments as defined by TISS (11). Factors found to
be most important to determine this probability were: diagnosis,
APACHE III score, age, operative status and prior location in
hospital as well as duration of hospitalization (11, 12). Taking this
a step further, a model was developed to predict the likelihood
of low risk monitor patients receiving one of the same 35 active
life-supporting treatments as defined by TISS after their first ICU
day in an attempt to identify patients who may not need ICU
admission (13).
Low Risk Monitoring
The composite metric of Low Risk Monitoring (LRM) has
been developed based on APACHE and TISS to assess ICU
resource utilization, specifically determining the percentage of
ICU patients admitted to the ICU for monitoring rather than
receiving treatment(s) that by general consensus typically require
an ICU setting. LRM is defined as the fraction of ICU patients
with <10% risk of ICU mortality as determined by APACHE
scoring (“low risk” component) who do not get ICU specific
treatments in their first ICU day or “APACHE Day” as defined
by APACHE rules (“monitoring” component). The rationale for
knowing the percentage of ICU patients who receive monitoring
but no active treatments during their first ICU day is that a
fraction of these patients may not require precious ICU resources
and therefore could more cost-effectively be managed in a lower
level care setting.
For the purpose of calculating LRM%, “active treatment”
is defined not by subjective assessment, but by TISS. This is
important as it illustrates that there are potentially subgroups of
patients who are receiving treatments different from the 35 TISS
treatments. These patients would be classified as “monitored”
by TISS, even though their non-TISS treatment may be labor-
intensive and necessitate and benefit from an ICU setting. Having
said that, the TISS list was designed to be inclusive and capture
ideally all relevant ICU related treatments. It was, however, last
updated over 34 years ago. It is unclear to what extent TISS
is missing phenotypes of ICU patients in different specialty
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ICUs and whether those patients are best cared for in an ICU
setting. On the other hand, it is likely that potential novel non-
TISS ICU treatments will be indirectly captured, because they
necessitate other TISS ICU treatments along with them (i.e.,
patients undergoing invasive CNS monitoring techniques will
also need to be sedated and mechanically ventilated). A very
important aspect of triage decisions and ICU utilization are
nurse-to-patient ratios. There is data to suggest that a portion
of LRM ICU admissions might be driven by patients with rather
uncomplicated monitoring requirements but primarily intensive
nursing needs (14). These patients too, would benefit from the
ICU setting.
A commonly used framework for monitoring LRM as
an ICU utilization metric is based on tele-ICU monitoring
technology and software used in ∼11–15% of ICUs in the US
(eCare ManagerTM, Philips, Netherlands) (15, 16). There are
some notable differences between the TISS active ICU specific
treatments and APACHE active treatments as used by the
tele-ICU monitoring software we are reporting on which are
summarized in Table 1.
The characteristics and differential outcomes of LRM patients
in Neuroscience Critical Care Units are sparsely reported on.
The purpose of this study is to describe the LRM patient
population and compare it to actively treated patients (AT) in
our tertiary/quaternary care center Neuroscience-ICU. We also
discuss the practice guidelines, policies, and expert consensus
recommendations that address and influence LRM triage
decisions for the Neuroscience ICU patient population.
MATERIALS AND METHODS
The Institutional Review Board of New York Medical
College/Westchester Medical Center approved this study
under “exempt approval” category (Reference number WMC
L12-240). Patients admitted to the Westchester Medical Center
Neuroscience-ICU in 2016 and 2017 were retrospectively
identified. The following patients were excluded from the
analyses: patients with ICU length of stay (LOS) <4 h, patients
younger than 18 years of age, patients with invalid data points
and patients with missing data for APACHE IVa risk predictive
modeling. Patients were categorized according to whether
they received one or more of 32 ICU specific treatments in
their first ICU day (AT, Active Treatment) or not (LRM,
Low Risk Monitoring). We used APACHE IVa risk predictive
modeling built into our existing eICU coverage model (eCare
Manager 4.0.1, Royal Philips, Netherlands) to assess AT
vs. LRM comparative risks for ICU and hospital mortality
and length of stay. All patient characteristics like admission
diagnosis, primary managing subspecialty as well as data for risk
predictive modeling were extracted from the deidentified eCare
Manager derived research database (eSearch 5.2; Royal Philips,
Netherlands). Admission diagnosis categories follow APACHE
IVa methodology. Every admission to the Neuroscience ICU
was reviewed in detail and in real time by a board certified
intensivist, who then entered admission source and comorbidity
information necessary for APACHE IVa predictive scoring
and assigned the most appropriate out of APACHE IVa
non-surgical and surgical Neuroscience diagnostic categories
(30 medical admission diagnostic categories: neurologic
abscess, amyotrophic lateral sclerosis, coma, cerebrovascular
accident/stroke, drug withdrawal, encephalitis, encephalopathies,
Guillain-Barre syndrome, epidural hematoma, subdural
hematoma, intracranial hemorrhage/hematoma, obstructive
hydrocephalus, meningitis, myasthenia gravis, neurologic
neoplasm, non-traumatic coma due to anoxia/ischemia,
nine categories of Overdoses, cranial nerve palsy, carbon
monoxide/arsenic/cyanide poisoning, seizures, subarachnoid
hemorrhage and Neurologic Medical, Other; 26 surgical
admission diagnostic categories: surgery for abscess/infection,
vascular anastomosis, surgery for arteriovenous malformation,
brain biopsy, Burr hole placement, surgery for cerebrospinal
fluid leak, surgery for complications of previous spinal cord
surgery, cranial nerve decompression/ligation, cranioplasty
and complications from previous craniotomies, devices for
spine fracture/dislocation, spinal fusion, surgery for subdural
hematoma, surgery for epidural hematoma, surgery for
intracranial hemorrhage/hematoma, laminectomy, surgery for
cranial neoplasm, surgery for spinal cord neoplasm, surgery
for intractable seizures, shunts and revisions, other spinal cord
surgery, stereotactic procedure, surgery for subarachnoid
hemorrhage/intracranial aneurysm, sympathectomy,
transsphenoidal surgery, ventriculostomy and Neurologic
Surgery, Other). For both surgical and medical admissions the
categories Neurologic Surgery, Other or Neurologic Medical,
Other were selected if no other available category provided a
more accurate classification. Univariate statistical comparisons
of patient characteristics were performed using the unpaired
t-test for continuous variables and Fisher’s exact test for
dichotomous variables, both with a significance criterion of
p < 0.05 (Graphpad Prism, Graphpad Software, US).
RESULTS
There were a total of 1,724 admissions to the Neuroscience-
ICU in 2016 and 2017. Seventeen admissions were excluded
due to ICU LOS < 4 h, four admissions were excluded due to
missing Admit source and one admission was excluded due to
missing hospital discharge location. 1,702 (98.7%) admissions
without any exclusion criteria remained for 2016 and 2017
and were included in the analysis. 968 (56.9%) of those 1,702
admissions were in the LRM category, and 734 (43.1%) were
in the AT group. The mean age was not statistically different
between the LRM and AT groups (61.2 vs. 62.8 years, p = 0.83).
40.1% of patients in the LRM group and 39.5% of patients in
the AT group were female. The ethnicity distribution was very
similar in both groups (see Table 2). A similar percentage of
patients opted for “Do not resuscitate” status in the LRM and
AT groups (9.1 vs. 8.9%, respectively). Readmission rates were
similar in the LRM and AT groups, both within 48 h of ICU
discharge and later than 48 h after ICU discharge (LRM group:
1.4% <48 h, 5.4% overall, AT group: 2.5% <48 h, 4.8% overall).
Patients in the AT group had significantly higher APACHE IVa
scores compared to the LRM group (57.3 ± 0.91 vs. 39.8 ±
0.49, p < 0.0001). The top 7 admission diagnoses overall were
cerebrovascular accident/stroke (391 cases, 23.0%), intracranial
hemorrhage/hematoma (195 cases, 11.5%), other neurologic
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TABLE 1 | List of “active treatments” by organ system (left column) and compared as per therapeutic intervention scoring system (TISS) (second column) and Acute
Physiology, Age and Chronic Health Evaluation (APACHE) Iva/tele-intensive care unit monitoring software (third column).
Active treatments per
Category TISS (9, 10) APACHE (5–8) Substantive Difference
Respiratory Controlled ventilation Controlled ventilation None
Controlled ventilation with muscle relaxant Controlled ventilation with muscle relaxant None
IMV or Assisted Ventilation IMV or Assisted Respirations None
Spontaneous PEEP or CPAP Spontaneous PEEP or CPAP or BiPAP BiPAP included in APACHE
Nasal or oral intubation Nasal or oral intubation (ICU) Qualifier “Emergency” in TISS;
Qualifier “ICU” in APACHE
Fresh tracheostomy (<48 h) Fresh tracheostomy (<48 h) None
Emergency bronchoscopy Bronchoscopy (ICU) Qualifier “Emergency” in TISS;
Qualifier “ICU” in APACHE
Cardiovascular Atrial or ventricular pacing Atrial or Ventricular pacing (active) Qualifier “Active” included in APACHE
Intraaortic balloon IABP (active) None
Vasoactive drug (1) Vasoactive drug (1) None
Vasoactive drugs (>1) Vasoactive drugs (>1) None
Intravenous antiarrhythmic Continuous antiarrhythmic IV Qualifier “Continuous” included in
APACHE
>6 L/d intravenous fluids >6 L/d intravenous fluids None
Rapid blood transfusion Rapid blood transfusion None
Post-arrest Post-arrest (24 h) Qualifier “24 h” added in APACHE
Trauma suit Trauma suit None
Cardioversion Cardioversion None
Pericardiocentesis Pericardiocentesis (ICU) Qualifier “Emergency” in TISS;
Qualifier “ICU” in APACHE
Renal Stable hemodialysis Stable hemodialysis None
Unstable hemodialysis Unstable hemodialysis None
Gastrointestinal Intravenous pitressin infusion Intravenous vasopressin infusion None
Continuous arterial drug infusion Continuous arterial drug infusion None
Balloon tamponade for esophageal varices Balloon tamponade for esophageal varices None
Continuous nasogastric lavage Continuous nasogastric lavage None
Emergency endoscopy Endoscopy (ICU) Qualifier “Emergency” in TISS;
Qualifier “ICU” in APACHE
Neurologic Mannitol infusion Mannitol infusion (continuous or intermittent) Qualifier “continuous or intermittent”
added in APACHE
Ventriculostomy Ventriculostomy None
Treatment of Seizure Seizure (active)/treatment of metabolic
encephalopathy
Treatment of metabolic
encephalopathy added in APACHE
Induced hypothermia Induced hypothermia (<32C) None
Barbiturate anesthesia Barbiturate anesthesia None
Miscellaneous Treatment of metabolic acidosis or alkalosis Treatment of acidosis/alkalosis (complex) None
Emergency operation Emergency operative procedure None
Concentrated K intravenously n/a Not included In APACHE
Complex metabolic balance n/a Not included In APACHE
Active diuresis for fluid overload n/a Not included In APACHE
The substantive differences between the two frameworks are summarized in the right column.
surgery (79 cases, 4.6%), surgery for cranial neoplasms (78 cases,
4.6%), surgery for subarachnoid hemorrhage (75 cases, 4.4%),
medically managed subarachnoid hemorrhage (72 cases, 4.2%)
and Seizures (64 cases, 3.8%). The top seven admission diagnoses
overall accounted for 54.4% of LRM admissions and 58.2% of AT
admissions.
Actual ICU mortality was 0.8% in the LRM group vs. 15.4%
in the AT group. Actual hospital mortality was 3.7% in the
LRM group vs. 22.1% in the AT group. The ratios of observed-
to-predicted ICU and hospital mortality were below prediction
for the LRM group (0.25 and 0.50, respectively). The ratios
of observed-to-predicted ICU and hospital mortality were at
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TABLE 2 | Baseline patient characteristics and outcomes of low risk monitoring compared to active treatment admissions.
Neuroscience-ICU 2016–2017 LRM AT p-value
No. of ICU admissions (%) 968 (56.9) 734 (43.1)
Age (mean ± SEM) 61.2 ± 0.58 62.8 ± 0.63 0.06 (NS)
Female % 40.1 39.5 0.83 (NS)
Caucasian % 67.9 71.3 0.14 (NS)
African American % 10.7 10.1 0.69 (NS)
Hispanic % 8.9 9.4 0.73 (NS)
Asian % 2.2 1.2 0.19 (NS)
Other % 10.3 8.0 0.12 (NS)
Do not resuscitate status % 9.1 8.9 0.93 (NS)
Readmission % 5.4 4.8 0.66 (NS)
Readmission <48 h % 1.4 2.5 0.15 (NS)
APACHE IVa (mean ± SEM) 39.8 ± 0.49 57.3 ± 0.91 <0.0001 (****)
Top 7 admission diagnoses (n, %) 527 (54.4) 427 (58.2) 0.13 (NS)
Cerebrovascular accident/Stroke 235 (24.3) 156 (21.3) 0.15 (NS)
Intracranial hemorrhage 95 (9.8) 100 (13.6) 0.017 (*)
Neurologic surgery, Other 48 (5.0) 31 (4.2) 0.49 (NS)
Surgery for cranial neoplasms 39 (4.0) 39 (5.3) 0.24 (NS)
Surgery for subarachnoid hemorrhage 54 (5.6) 21 (2.9) 0.008 (**)
Subarachnoid hemorrhage 28 (2.9) 44 (6.0) 0.002 (***)
Seizures 28 (2.9) 36 (4.9) 0.039 (*)
Actual ICU mortality (n, %) 8 (0.8) 113 (15.4) <0.00001 (*****)
Predicted ICU mortality (%) 3.2 14 <0.0001 (****)
Actual Hospital mortality n, (%) 36 (3.7) 162 (22.1) <0.0001 (****)
Predicted hospital mortality (%) 7.4 21.9 <0.0001 (****)
Primary neurosurgery Mgmt (%) 67.3 68.9 0.49 (NS)
Primary neurology Mgmt (%) 15.9 13.4 0.17 (NS)
Primary internal medicine/CCM management (%) 2.1 5.2 0.0003 (***)
Primary Mgmt by other (%) 14.7 12.5 0.15 (NS)
APACHE IVa scores are measured as dimensionless whole numbers between 0 and 200. NS, non-significant. Asterisks denote increasing levels of statistical significance: *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, *****p < 0.00001.
or slightly above prediction for the AT group (1.1 and 1.0,
respectively).
Neurosurgery primarily managed 67.3% of LRM patients
and 68.9% of AT group patients, whereas Neurology managed
15.9% of LRM patients and 13.4% of AT patients. There
was a significantly higher admixture of medically critically
ill patients primarily managed by Pulmonary/Critical Care
Medicine in the AT group vs. the LRM group [5.2 vs. 2.1%,
respectively (p = 0.0003)]. All patient characteristics (average
APACHE scores, predicted ICU and hospital mortality, actual
and predicted ICU and hospital length of stay) were statistically
significantly different between LRM and AT patients (see
Table 2).
DISCUSSION
A reasonable and universally accepted standard of LRM% for
ICUs in general and for different subspecialty vs. mixed patient
populations does not exist. In general, a national average across
all comers ICUs in the United States (US) today of LRM% in ICU
settings is around 35.4% of low risk patient stays (14). A variety
of factors influence observed LRM% between different patient
populations, ICUs and hospitals (also see Table 3):
1. Hospital geographic setting (urban vs. rural),
2. Hospital overall size as well as ICU bed to general floor bed
ratios,
3. Hospital category (academic vs. community vs. hybrid),
4. Presence or absence of intermediary or specialty care units,
5. Staffing models (low vs. high intensity staffing for MDs, RNs
and other ancillary staff),
6. Overall Hospital ICU bed utilization/occupancy
rates.
A retrospective single center study (Mayo Clinic, Rochester,
MN) characterized the percentage of LRM patients in their
medical ICU as 22.1%, surgical ICU as 45.7%, mixed medical-
surgical ICU as 30.7% with an overall average of 37.2% (17).
ICUs specializing in postoperative care of complex surgical
procedures like cardiothoracic procedures, transplantations
and complex neurosurgical procedures in general and
almost by definition have a low percentage of LRM patient
stays, as their management will inevitably involve multiple
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TABLE 3 | List of factors influencing the percentage of low risk monitoring
patients for any given hospital and intensive care unit (ICU).
Hospital Geographic setting
Urban
Suburban
Rural
Hospital size
ICU bed to general floor bed ratio
Hospital category
Academic
Community
Hybrid
Intermediary or observation units
Present
Absent
Intermediary care to ICU bed ratio
ICU ICU staffing models
High intensity
Low intensity
ICU bed occupancy rates
ICU type Subspecialty specific
Mixed
ICU physician coverage model “Closed” or intensivist
primary coverage
Co-management model
“Open” coverage model
Patient Average patient acuity
In general, factors can be divided into hospital specific, ICU specific and patient specific.
active treatments addressing hemodynamic management or
mechanical ventilation. Certain subspecialty ICUs are generally
expected to host higher percentages of patient stays for purposes
of maximal monitoring for deterioration/complication, i.e.,
monitoring for arrhythmias in cardiac care units, monitoring
for changes in neurological status in Neuroscience ICUs
or monitoring for limb or organ perfusion in surgical
ICUs.
At WMC the Neuroscience Critical Care Unit consists of
17 ICU beds and 12 Intermediate Level Care beds (Step down
beds). Only the 17 ICU beds are staffed by neurointensivists in
an “open” co-management model, meaning Neurosurgery and
Neurology patients are co-managed by Pulmonary/Critical Care
consultants for the general Critical Care aspects of their care like
ventilator management, best practices etc. The LRM to AT ratio
of our Neuroscience ICU has to be kept in perspective to our ICU
to stepdown bed ratio of 17:12 and the absence of a specialized
stroke unit. LRM to AT ratios may be significantly different in
care settings with different ICU to intermediate care level bed
ratios or specialized stroke units.
Our institution started an electronic ICU program in January
of 2016. The electronic ICU is staffed 24/7/365 by critical
care trained nurses and doctors who monitor and assist the
bedside ICU team without altering the bedside staffing model.
The electronic ICU comprehensively evaluates all patients on
admission to the ICU, monitors and assists with best practice
compliance, standardizes care practices, monitors for any signs
of decompensation and assists the bedside team in times of crisis.
The electronic ICU also gathers and enters all data relevant for
APACHE IVa risk predictive modeling (classification by surgical
and non-surgical APACHE IVa admission diagnostic categories,
comorbidities, admission source) and provides comprehensive
quarterly performance reviews to ICUs (including observed
and predicted ICU and hospital mortality, length of stay and
ventilator durations, transfusion practices, glucose management,
stress ulcer prophylaxis, venous thromboembolism prophylaxis,
lung protective ventilation strategy).
56.9% of patients who were admitted to our Neuroscience
ICU in 2016 and 2017 were classified as LRM, whereas 43.1%
were classified as AT. A recently published single center large
case series on 1,879 patients reports similar distributions of 46.5%
LRM to 53.5% AT for a 16 bed academic hospital neurological
ICU (18). The two most frequent admission diagnoses were
the same for LRM and AT categories (stroke and intracranial
hemorrhage/hematoma), illustrating that further differentiating
factors like time from onset of symptoms, NIH stroke scale
scoring and radiographic extent of brain tissue involvement
determine whether a patient is a candidate for and will likely
benefit from active treatment as opposed to monitoring only.
Patients with intracranial hemorrhage were 1.4 times more
likely to be actively treated than primarily monitored without
ICU specific treatments (p = 0.017). Patients with SAH were
represented in the respective surgical admission category for
SAH if they were admitted to the Neuroscience ICU after
surgical aneurysm clipping or neuroendovascular intervention
for aneurysm/intracranial AVM. They were represented in the
medical category for SAH if they did not undergo surgery
or neuroendovascular intervention. Patients with surgically
managed SAH were about twice as likely to be in the
LRM group (postoperative observation) than in the AT group
(postoperative active management) (5.6 vs. 2.9%, p = 0.008),
whereas medically managed patients with SAH were about twice
as likely to be in the AT group as compared to the LRM group
(6.0 vs. 2.9%, p = 0.002). This inverse LRM-AT distribution
between surgically and medically managed SAH patients may be
attributable to more acute and initial presentations of SAH in
the medical group requiring aggressive management vs. patients
as opposed to more subacute patients in the surgical category
who got admitted to the Neuroscience ICU after they had
their aneurysm or AVM surgically secured, with their main
focus being on prevention of complications. A plethora of
postsurgical conditions and medical neurological conditions,
jointly classified as “Postsurgical, other” or “Neurologic Medical,
Other” were being admitted as LRM, which reflects the
diversity of Neuroscience ICU patient populations in our
tertiary and quaternary University hospital setting which do
not fit more accurately in any of the other available 30
medical or 26 surgical APACHE IVa admission diagnosis
categories (see Materials and Methods). Patients admitted to
the Neuroscience ICU with Seizures were significantly more
likely to be actively treated (4.9%) as compared to monitored
(2.9%). The reason for this is that any pharmacologic treatment
for seizures and metabolic encephalopathy counts as active
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treatment as per eCM criteria (see Table 1). This may have
falsely lowered the LRM group in this particular ICU as
compared to TISS standards. Patients in our Neuroscience ICU
are co-managed by either Neurosurgery or Neurology Primary
Attendings and Consulting Pulmonary/Critical Care/Neuro-
Critical Care Certified Intensivists. There was a significantly
disproportionate admixture of “boarding” patients primarily
managed by Pulmonary & Critical Care attendings in the AT
over the LRM group (5.2 vs. 2.1%; p = 0.0003), which likely
caused an increase in actual and predicted ICU and hospital
mortality, given that the medically critically ill patient population
at our institution has high acuity scores and high mortality
rates.
Which Practice Guidelines and Policy
Statements Provide Guidance for Low Risk
Monitoring in Neuroscience ICUs?
There is clear evidence that patients with acute strokes have
improved outcomes when treated in specialized stroke units
or units with centralized expertise and case volume in stroke
care (19, 20). The American Heart Association/American Stroke
Association Guidelines for the early management of patients
with acute ischemic stroke advocate admission to specialized
ICU for monitoring of mental status and neurological deficits,
as well as management of oxygenation levels, blood pressure,
heart rate, body temperature and blood glucose levels as well
as to monitor for complications from anticoagulation (21). It
is well-known that after initial stroke assessment up to 26%
of patients will have a subsequent deterioration in their status
(10% due to progression of ischemic stroke, 10% due to cerebral
edema and roughly 3% each due to secondary hemorrhagic
or ischemic events) (21). The leading complications of acute
ischemic strokes are related to dysphagia and/or alterations
in mental status (pneumonitis, pneumonia), followed by heart
failure and gastrointestinal bleeding (22). Interestingly, the
guidelines do not directly address ICU level monitoring for
patients specifically after systemic or local pharmacologic or
mechanical thrombolysis, either, or intracranial acute angioplasty
and stenting, but clinically it is intuitive that these post-
procedural patients should be monitored for signs of side
effects/complications. The complications of thrombolysis are
symptomatic intracerebral hemorrhage, systemic hemorrhage
events or thrombolytic related angioedema.
Which Acutely Critically Ill Patient
Populations Might Be Missed by the
TISS/APACHE Active Treatment List and
Therefore Misclassified as LRM?
The TISS list of active ICU treatments has last been updated in
1983. A plethora of new treatment modalities has entered the
market since that time. A large number of new ICU treatments
will, however, be indirectly captured as due to their invasive or
complex nature they will need other treatments along with them
that are captured by TISS, e.g., invasive neuro-monitoring will
need mechanical ventilation, vasoactive infusions and sedation.
TISS does not include frequent airway clearance/suctioning as an
active treatment, which can often be problematic after neurologic
injury. Given that this treatment modality usually applies to
patients long after their first ICU day (after extubation or
tracheostomy/ventilator weaning), misclassifications of patients
who receive only this active treatment as LRM is extremely
unlikely, given that the timeframe focus of the LRMmetric is the
first ICU day.
How Does LRM% Relate to Other ICU
Performance Metrics?
A study by Zimmerman et. al. on 359,715 patients from 108
medical, surgical, and mixed medical-surgical ICUs has shown
that the percentage of LRM patients is inversely correlated with
ICU performance, i.e., the nine best performing units (lowest
ICU and hospital mortality ratios and LOS) had the lowest
LRM%, whereas the nine worst performing ICUs (highest ICU
and hospital mortality and LOS ratios) had the highest LRM%
for medical, surgical and mixed medical-surgical units alike (23).
Strengths and Limitations
The current study contains admission data for 2016–2017. This
is an advantage as the admissions all represent the current care
approach and effects of changes over time are minimal. The
disadvantage lies in the fact that the overall admission numbers
are lower than for studies over longer periods of time. Multiple
year studies also can address the question of seasonal variations
in LRM%. In addition, the aforementioned ICU in this citation is
part of a 1,000 bed academic tertiary and quaternary care center
with very high Case Mix Indices and may not be representative
of different types of hospitals or hospital systems.
CONCLUSIONS
Differentiating patients admitted to our Neuroscience ICU into
those who received active ICU specific treatments during their
first 24 h in the ICU (AT group, 43.1% of patients) and those who
had a low ICU mortality risk (<10%) and a primary focus on
monitoring during their first 24 h in the ICU (LRM group, 56.9%
of patients) was highly discriminatory for APACHE IVa acuity
scores and all APACHE IVa derived risk predicted outcomes
(actual and predicted ICU and hospital mortality). LRM Patients
exhibited significantly lower APACHE IVa scores, ICU and
hospital mortality rates when compared to actively treated
patients. Observed-over-expected ICU and hospital mortality
ratios were better than predicted by APACHE IVa for low
risk monitored patients and close to prediction for actively
treated patients. This constellation of findings suggests that
at least a subset of our LRM patients may safely and more
cost effectively be cared for in intermediate level care settings,
enabling redistribution of ICU resources to higher acuity patients
in need of ICU treatments. In addition, patients with Acute
Strokes accounted for 391 out of 1,702 overall Neuroscience ICU
admissions (23%) and were equally represented in both LRM
(24.3%) and AT groups (21.3%) (p = 0.13). American Heart
Association/American Stroke Association Guidelines advocate
admission to specialized intensive care units or specialized stroke
units with centralized expertise in the early management of acute
strokes. Hospitals with high numbers of Acute Stroke patients
Frontiers in Neurology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 938
Becker et al. Neurocritical Care Low Risk Monitoring
like ours might benefit from the creation of specialized stroke
units.
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